Allogeneic hematopoietic SCT (HSCT) for children with standard-risk AML in first CR (CR1) is controversial. We reviewed 32 consecutive children with standard-risk AML who received matched sibling donor HSCT in CR1 from 1995 to 2004. With a median follow-up of 76 months (range: 36-114), 3 year EFS was 0.74 (95% confidence interval (CI): 0.57-0.88) and the overall survival was 0.81 (95% CI: 0.66-0.93). Only one patient died as a result of TRM. Larger studies, such as the MRC-UK 10 and 12, reported 60-62% EFS. Outcome of children with standard-risk AML transplanted from a matched sibling donor in CR1 is very encouraging with minimal toxicity.
Introduction
In recent years, there has been a significant improvement in the outcome of children with standard-risk AML treated with chemotherapy alone. This has been achieved by a combination of increasingly intensive anthracycline-and cytosine-based chemotherapy and advances in supportive care, which have allowed intensive chemotherapy to be delivered with less morbidity and mortality. 1 In the Medical Research Council of United Kingdom (MRC-UK) trials 10 and 12, children with standard-risk AML were allowed to proceed to hematopoietic SCT (HSCT) if there was a fully matched sibling donor. 2 Allogeneic HSCT enables the administration of high-dose chemotherapy to eradicate leukemia and provides the benefit of the GVL effect, and when using an HLA-matched sibling donor, HSCT has been considered to be the treatment of choice for children with AML in CR1. [3] [4] [5] However, with the excellent results obtained with chemotherapy and the known risks and longterm side effects of HSCT, the decision remains controversial. Although it is generally acceptable not to transplant children with favorable risk AML in CR1 and to transplant the poor-risk group with related or unrelated donors, the majority of the patients (more than 2/3) fall in the standard-risk group. In our institution and generally in North America, children with standard-risk AML and a fully matched sibling donor are usually offered HSCT in CR1. With the added GVL effect, their outcome is expected to be better than chemotherapy alone. However, increasing TRM from HSCT may change this balance. The current study examined the outcome of HSCT in children with standard-risk AML receiving fully matched sibling donors in CR1 to ascertain if it is justifiable to continue offering HSCT to these children despite the reasonably good results obtained with chemotherapy alone.
Patients and methods
This study was approved by our institutional review board. The health records of children who received HSCT for a diagnosis of standard-risk AML in the Hospital for Sick Children (Toronto) from November 1995 to November 2004 were reviewed. The definition of standard-risk was according to the following MRC-UK criteria: (1) no favorable cytogenetics; t(8;21), t(15;17) or inv (16) abnormalities; (2) no unfavorable cytogenetics; monosomy 7, monosomy 5, del (5q), abn (3q) and complex karyotype; (3) no resistant disease; 420% blast after the first course of chemotherapy. Patients with mixed lineage/bipheotypic acute leukemia, Down's syndrome or M3 (acute promyelocytic leukemia) were excluded from the study. All patients were to be in morphological remission before HSCT. Donor sources were fully HLA-matched siblings. HLA matching consisted of either serologic or low-resolution molecular typing of HLA-A and HLA-B and molecular typing for DRB1 using high-resolution techniques. A fully matched sibling was defined as a 6/6 match on A, B and DRB1 loci. Unmanipulated BM was collected according to established methods. 6 All patients had indwelling central venous catheters, and the majority received nutritional support with total parenteral nutrition. Our institutional criteria to start total parenteral nutrition were as follows: if a child failed to maintain caloric and protein intake of 50% of their expected requirement for 1 day, in case of children less than 2 years of age, and 2-3 days, in case of children over 2 years of age; total parenteral nutrition was started empirically if there was pre-existing failure to thrive pre-HSCT. Infection prophylaxis included fluconazole for fungal prophylaxis, 7 ganciclovir for CMV prophylaxis, 8, 9 growth factors and i.v. immunoglobulin as well as the use of laminar airflow rooms from day 0 onward. Pneumocystis pneumonia prophylaxis was given for at least 6 months post-HSCT and pneumococcal prophylaxis with penicillin continued for at least 1 year or until the administration of pneumococcal vaccine. Neutrophil engraftment was defined as the first of 3 consecutive days, following the neutrophil nadir, of ANC 40.5 Â 10 9 /l, and platelet engraftment was defined as the first of 3 consecutive days of unsupported platelets 420 Â 10 9 /l. Primary graft failure was defined in patients surviving beyond day þ 28 as failure to attain an ANC 40.5 Â 10 9 /l before death or receipt of a second graft. Clinical grading of acute GVHD was performed according to previously reported criteria. 10 Chronic GVHD was diagnosed and classified according to standard criteria. 11 Tissue biopsy samples were obtained to confirm GVHD diagnosis whenever clinically indicated and feasible. EFS, overall survival (OS), cumulative incidence of TRM and cumulative incidence of relapse were described according to the Kaplan-Meier method. In the determination of EFS, death, relapse, graft rejection and graft failure were considered as events. TRM was defined as any death in remission.
Results
Patient and transplant characteristics and outcome are summarized in Table 1 . Thirty-two consecutive children diagnosed with standard-risk AML, and having a matched sibling donor, received HSCT in CR1 during the study period. Upfront AML chemotherapy has changed during the study period. Pediatric Oncology Group (POG) 9421 protocol was used in the first half of the study and the MRC-UK 10 protocol was used in the second half of the study as initial chemotherapy to achieve CR1. The number of chemotherapy courses varied between patients but mostly 2-4 courses were delivered before HSCT. All patients were in morphological remission before HSCT, and all patients received unmanipulated fresh BM on the same day it was harvested. The total nucleated cell dose aimed was 4 Â 10 8 per kg recipient body weight. Nonetheless, the total nucleated cell dose varied from 1.6-6.9 Â 10 8 per kg recipient body weight. Engraftment of white cells occurred at a median of 20 days (range: 11-32). There was no primary graft failure. Depending on donor and bed availability, time from diagnosis to HSCT varied with a median of 4.2 months (range: 1.9-7.1). All patients received myeloablative-conditioning regimens. These included the following: BU every 6 h over 4 days plus CY 50 mg/kg over 1 h daily for 4 days in 23 patients (BU/CY); CY 50 mg/kg over 1 h daily for 4 days followed by fractionated TBI (fTBI; 1200 cGy) in six fractions in 4 patients (CY/fTBI); single dose VP16, 60 mg/kg, followed by fTBI (1200 cGy) in six fractions in 4 patients (VP16/ fTBI) and BU dose-adjusted (AUC 900-1300) every 6 h over 4 days plus single dose (180 mg/m 2 ) melphalan in 1 patient (BU/Mel). GVHD prophylaxis was with CsA at 3 mg/kg/day starting at day À1 and a short course of MTX at a dose of 10 mg/m 2 i.v. at day þ 3, þ 6, þ 11 and þ 18. One patient died from TRM due to acute respiratory failure secondary to diffuse alveolar damage; he was conditioned with CY/fTBI. Eight patients (25%) relapsed and six died due to disease progression. Two relapsed patients received a second HSCT, one of whom continued to be in remission for 7.5 years after the second HSCT and is a long-term survivor, whereas the other suffered another relapse 18 months after the second HSCT and at the time of writing this report, he is in remission after receiving donor leukocyte infusion from his sibling. Incidence of acute severe (grade III or IV) GVHD and chronic extensive GVHD was less than 5% (one patient in each category). For a median follow-up of 76 months (36-114), 3 year EFS was 0.74 (95% CI: 0.57-0.88) and OS was 0.81 (95% CI: 0.66-0.93). Figure 1 illustrates the EFS and OS for all the patients. Figure 1 also illustrates that the two patients who were salvaged with a second HSCT had a relatively late relapse after the first HSCT, at 16 and 22 months, respectively. Patients who relapsed early, defined as less than 1 year from HSCT, died due to progressive disease.
Discussion
While acknowledging the limitations of a small patient cohort, non-randomized, single-arm study in reaching a Table 1 Demographics and outcome of 32 consecutive pediatric standard-risk AML patients transplanted in CR1 from a fully matched sibling donor
Parameter Results

Total number 32
Sex Male (%) 16 ( definitive conclusion, our study indicates that the outcome of HSCT from fully matched sibling donors for children with standard-risk AML in CR1 is encouraging with minimal toxicity. Standard-risk features were based on the large MRC-UK pediatric trials, and the outcome of standard-risk children with AML in MRC-UK 10 was an OS of 52%. 2 The results of MRC-UK 12 remain immature; however, preliminary results showed that, for standard-risk group, disease-free survival was 62%. 2 Our results with HSCT in CR1 for standard-risk AML is superior compared to MRC-UK trials 10 and 12, with an EFS of 74% and OS of 81%. We acknowledge the limitation of the small number of patients in the current study, and we acknowledge the fact that our study did not look at the 'intentionto-treat' basis, as did the MRC-UK studies. However, this is a single institution study where there is a uniform HLAtyping and transplant and supportive care technology. All patients received myeloablative-conditioning regimens with 470% of them receiving BU/CY. TBI was used in eight patients due to physician preference and/or in patients who were central nervous system-positive at the time of initial diagnosis. There is, however, no convincing evidence that TBI is needed in AML. 12 Therefore, children who were transplanted toward the second half of the study, even if they were CNS-positive, received BU/CY. Furthermore, all patients received a uniform GVHD prophylaxis.
While in the past all children with AML were considered for HSCT in CR1, particularly if there was a related donor, with the current state-of-the-art intensive chemotherapy, this decision remains controversial and is a challenge for many oncologists. Large studies conducted by the Children Cancer Group (CCG): CCG 251, CCG 213 and CCG 2891 have proven that the outcome of children with AML receiving a related donor HSCT in CR1 is superior compared with chemotherapy alone. 13 Moreover, a recently published study conducted by the same group, CCG 2961, again demonstrated significantly better disease-free survival for children with AML receiving related donor HSCT is CR1 versus chemotherapy alone (60 versus 50%,
14 In our study, only one patient died from TRM (o5%). This very-low TRM incidence could be explained by the fact that all these CR1 patients received fully matched sibling donors along with the better organ function and less infectious complications in CR1 patients compared with relapsed patients receiving HSCT. This TRM incidence in CR1 HSCT patients is even lower than the upfront chemotherapy infection related mortality incidence recently published for 492 children with AML in the CCG 2961. 15 Our study also illustrates that relapse after HSCT, when delayed, could be amenable to salvage therapy and repeat HSCT or donor leukocyte infusion with durable survival. In conclusion, offering HSCT to children with standard-risk AML who have a fully matched HLA sibling, in spite of the reasonably good results with chemotherapy alone, is reasonable because of the excellent outcome with minimal toxicity. 
